Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for possible side effects from Pembrolizumab and IO102-103. In addition, participants will be monitored for any delays to their surgery due to the study drugs.
This description comes directly from the study's public registry record.
Wojciech K Mydlarz, M.D., FACS · (301) 896-3332 · mydlarz@jhmi.edu
Zubair Khan, M.D. · 410-955-3157 · zkhan@jhmi.edu
Always discuss trial participation with your own doctor first.
| Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Not Yet Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Providence Cancer Institute | Portland, Oregon, United States | Not Yet Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05977907